

Agreement between Rare Partners and Fondazione Telethon

Milano 2nd March, 2015. To encourage the development of innovative therapeutic applications and new diagnostic systems based on the results of research funded by their calls, Fondazione Telethon has entered into a new agreement with Rare Partners, a non-profit company founded in 2010 in Milan and dedicated to the development of new therapies and diagnostic tools in the field of rare diseases.

Under the agreement, Rare Partners will provide Telethon with its expertise and its network of experts for analysis activities of regulatory pathways and support in preparation for clinical development of potential therapeutic applications.

Rare Partners will attend the Telethon Convention in Riva del Garda from 9 to 11 March 2015. At this meeting, Telethon-funded researchers can meet with Rare Partners to present, in a non-confidential way, their projects and discuss possible prospects for therapeutic development.

Rare Partners

Rare Partners Srl is a non-profit organization dedicated to the development of new therapies and diagnostics in the field of rare diseases.

The company, founded in Milan in March 2010 and registered as a Social Enterprise, constitutes a new opportunity for collaboration between the non-profit world, the scientific community and companies in the pharmaceutical and biotechnology sector.

Rare Partners aims to be a virtual company developing products through a network of partnerships with research institutions, charities and service companies, combining the use of non-profit financial resources (public and private) with their skills in industrial development.

For further information: www.rarepartners.org

The Fondazione Telethon

The Telethon Foundation is a non-profit organization recognized by the Ministry of Education and Research that supports research on rare genetic diseases. Precisely because of their rarity, these diseases, in most cases, have no cure or treatments and are often overlooked by public and private funding.

Founded in 1990 by a group of patients with muscular dystrophy, its mission is to find a cure for rare genetic diseases through scientific research of excellence, selected according to the best practices recognised at the international level.

Since its founding Telethon has invested over 420 million Euros in research, and has funded 2,532 projects with 1,547 researchers involved who have studied 450 diseases. Currently 371 Italian laboratories are engaged in Telethon-funded projects, and Telethon researchers have published more than 10,000 articles in international scientific journals.

For further information: www.telethon.it